KARYOPHARM THERAPEUTICS

for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy... Neutropenia: XPOVIO can cause life-threatening neutropenia, potentially increasing the risk of infection... Monitor more frequently during the first 3 months of treatment. Consider supportive measures, including antimicrobials and growth factors (e.g., G-CSF). Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Also known as: Karyopharm Therapeutics Inc